Table 1.
Summary of Participant Characteristics Pooled for dTpa Formulation (Primary Phase)—Exposed Set
| Characteristic | RSV120_dTpa (n = 101) | RSV120_Placebo (n = 101) | RSV60_dTpa (n = 103) | RSV60_Placebo (n = 102) | dTpa_Placebo (n = 102) | Total (n = 509) |
|---|---|---|---|---|---|---|
| Age at vaccination, y, mean (SD) | 31.4 (7.6) | 31.0 (8.0) | 30.8 (8.4) | 30.5 (8.3) | 30.4 (7.9) | 30.8 (8.0) |
| Age category at vaccination, y, No. (%) | ||||||
| 18–32 | 56 (55.4) | 56 (55.4) | 59 (57.3) | 58 (56.9) | 58 (56.9) | 287 (56.4) |
| 33–45 | 45 (44.6) | 45 (44.6) | 44 (42.7) | 44 (43.1) | 44 (43.1) | 222 (43.6) |
| Country, No. (%) | ||||||
| Belgium | 29 (28.7) | 29 (28.7) | 30 (29.1) | 29 (28.4) | 29 (28.4) | 146 (28.7) |
| Canada | 21 (20.8) | 20 (19.8) | 21 (20.4) | 22 (21.6) | 22 (21.6) | 106 (20.8) |
| United States | 51 (50.5) | 52 (51.5) | 52 (50.5) | 51 (50.0) | 51 (50.0) | 257 (50.5) |
| Ethnicity, No. (%) | ||||||
| Hispanic or Latinx | 11 (10.9) | 10 (9.9) | 3 (2.9) | 11 (10.8) | 9 (8.8) | 44 (8.6) |
| Not Hispanic or Latinx | 90 (89.1) | 91 (90.1) | 100 (97.1) | 91 (89.2) | 93 (91.2) | 465 (91.4) |
| Race, No. (%) | ||||||
| American Indian or Alaska Native | 3 (3.0) | 0 (0.0) | 1 (1.0) | 1 (1.0) | 0 (0.0) | 5 (1.0) |
| Asian | 1 (1.0) | 3 (3.0) | 2 (1.9) | 4 (3.9) | 4 (3.9) | 14 (2.8) |
| Black or African American | 4 (4.0) | 6 (5.9) | 8 (7.8) | 3 (2.9) | 4 (3.9) | 25 (4.9) |
| Native Hawaiian or other Pacific Islander | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| White | 91 (90.1) | 90 (89.1) | 90 (87.4) | 92 (90.2) | 91 (89.2) | 454 (89.2) |
| Other | 2 (2.0) | 2 (2.0) | 2 (1.9) | 2 (2.0) | 3 (2.9) | 11 (2.2) |
| BMI, kg/m2, mean (SD) | 26.8 (5.3) | 26.7 (5.2) | 26.9 (5.5) | 26.2 (5.7) | 26.9 (5.5) | 26.7 (5.4) |
Abbreviations: BMI, body mass index; dTpa, diphtheria, tetanus, and acellular pertussis; dTpa_placebo, participants who received dTpa and placebo; RSV, respiratory syncytial virus; RSV60_dTpa, participants who received RSV60 and dTpa; RSV60_placebo, participants who received RSV60 and placebo; RSV120_dTpa, participants who received RSV120 and dTpa; RSV120_placebo, participants who received RSV120 and placebo.